We are an iconic provider of hospital-based healthcare, striving to deliver an exceptional standard of care
We comprise several hospitals, health centres, a nationally accredited education provider and a world-class research institute
We are a nationally accredited, hospital-based Registered Training Organisation - the only one of its kind in Queensland
We are part of a collaborative research institute with The University of Queensland and founding partner of the Translational Research Institute
Health . Education . Research . Foundation
Cognitive Neurologist Professor Peter Nestor has been appointed to the position of Clinical Program Leader of the Neurosciences and Cognitive Health Program at Mater.
Simulation is a valuable tool used to educate and train health professionals. Where simulation involves models that are intended to replicate clinical or technical ...
Mater congratulates the four Mater People recognised in this year’s Australia Day Honours list.
Professor Vicki Flenady and her team at the Stillbirth Centre of Research Excellence (CRE) at Mater Research Institute – University of Queensland were awarded the UQ ...
Join the Miles for Miracles: Japan Trek 2019 and help give the best possible start to life for all babies born and cared for at Mater.
Dr Peter Steer has commenced his appointment as Mater Group Chief Executive Officer.
The 2017/2018 Mater Annual Review is now available online.
Researchers from Mater Research have been awarded more than $1.84 million in National Health and Medical Research Council (NHMRC) funding.
Mater Group is proud to mark a milestone in its history, the launch of a new brand, to reposition Mater as a group incorporating health, education and research for a ...
A Mater researcher has developed a method to predict breast cancer patient responses to a commonly prescribed breast cancer drug.
A new mobile phone app being trialled at Mater Mothers’ Hospital Brisbane aims to reduce the rate of stillbirth in Australia by 30 per cent by focusing on a baby’s kicks.
A new triple-combination drug trialled at Mater in Brisbane could increase the life expectancy of patients with cystic fibrosis (CF).
At Mater, we value effective communication—with staff, patients and the community. To keep up to date with news at Mater, you can review the latest news updates on this page or you can follow us or join the conversation on our social media pages.
A Media and Communications Officer is on-call 24 hours a day, seven days a week. To contact the on-call officer, please call Mater Switch on 07 3163 8111 and ask to be put through to the Media and Communications Officer on-call or give us online feedback